Federal Court Approves Surmodics Sale to GTCR
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Court Ruling on Surmodics Sale: A federal court allowed Surmodics' sale to GTCR to proceed after denying the FTC's request for a preliminary injunction to block the deal.
FTC's Concerns: The FTC had filed a lawsuit to prevent the $627 million sale, arguing that it would create anticompetitive conditions in the medical device coatings market.
Temporary Restraining Order: The judge granted a temporary restraining order until next Monday, giving the FTC time to decide on an appeal against the ruling.
Background of the Deal: GTCR agreed to purchase Surmodics for $43 per share in May of the previous year, which has raised concerns about market competition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
